3-Deazaadenosine: SAH Hydrolase Inhibitor for Methylation and Antiviral Research

Executive Summary: 3-Deazaadenosine is a potent, cell-permeable S-adenosylhomocysteine (SAH) hydrolase inhibitor (Ki = 3.9 μM), used to elevate intracellular SAH, thereby suppressing SAM-dependent methyltransferase activity and altering methylation-dependent pathways in vitro and in vivo [APExBIO Product]. Its established antiviral activity includes efficacy against filoviruses such as Ebola and Marburg in both primate and murine models [EpigeneticsDomain]. 3-Deazaadenosine provides a research tool to dissect the role of methylation in gene regulation, immune response, and viral replication (Wu et al., 2024). The compound is highly soluble in DMSO (≥26.6 mg/mL), moderately soluble in water (≥7.53 mg/mL with warming), but insoluble in ethanol, and should be stored at -20°C for stability. It is indispensable for workflow-optimized methylation inhibition and translational epigenetics research [3-Deazaneplanocin].

Biological Rationale

S-adenosylhomocysteine hydrolase (SAHH) is a conserved enzyme that catalyzes the reversible hydrolysis of SAH to adenosine and homocysteine (Wu et al., 2024). SAH accumulation inhibits SAM-dependent methyltransferases, modulating RNA, DNA, and protein methylation. Methylation plays a crucial regulatory role in gene expression, chromatin architecture, and cellular metabolism. Inflammatory responses and viral replication are both sensitive to changes in methylation status. For example, N6-methyladenosine (m6A) modification, catalyzed by METTL3/METTL14 complexes, is linked to mRNA stability and immune signaling, as shown in models of ulcerative colitis and viral infection (Wu et al., 2024). 3-Deazaadenosine enables researchers to precisely manipulate this regulatory axis by inhibiting SAHH and raising SAH levels, thereby suppressing methyltransferase activity and altering downstream methylation-dependent processes [EpigeneticsDomain].

Mechanism of Action of 3-Deazaadenosine

3-Deazaadenosine is a structural analog of adenosine, differing by the replacement of a nitrogen atom at position 3 of the adenine ring with a carbon atom. This modification confers potent inhibitory activity against SAH hydrolase (Ki = 3.9 μM) [APExBIO]. Upon treatment, 3-Deazaadenosine competitively inhibits SAHH, blocking the conversion of SAH to adenosine and homocysteine. Intracellular SAH rises, which acts as a feedback inhibitor of SAM-dependent methyltransferases, including those responsible for m6A RNA methylation and histone methylation (Wu et al., 2024). This leads to global hypomethylation and altered expression of genes involved in inflammation, apoptosis, and antiviral defense. The compound thereby provides a direct experimental tool to probe methylation’s role in cellular and viral biology.

Evidence & Benchmarks

• 3-Deazaadenosine inhibits SAH hydrolase with a Ki of 3.9 μM, resulting in SAH accumulation and methyltransferase inhibition (Wu et al., 2024, DOI).
• Preclinical studies show 3-Deazaadenosine suppresses m6A methylation in METTL14-regulated pathways, impacting inflammatory cytokine expression in murine colitis models (Wu et al., 2024, DOI).
• In vitro, the compound demonstrates antiviral activity against Ebola and Marburg viruses in primate and mouse cell lines (EpigeneticsDomain, link).
• Animal models confirm protective efficacy of 3-Deazaadenosine in lethal Ebola virus infection (APExBIO, link).
• The compound’s solubility profile is ≥26.6 mg/mL in DMSO and ≥7.53 mg/mL in water with gentle warming; it is insoluble in ethanol (APExBIO, link).
• Optimal storage is at -20°C; solutions are recommended only for short-term use to maintain compound stability (APExBIO, link).

This article offers updated mechanistic and translational perspectives beyond the foundational review at Hexa-His, by integrating the latest data on METTL14 and m6A modulation in inflammation.

Applications, Limits & Misconceptions

3-Deazaadenosine is primarily applied in preclinical research to study methylation pathways, test methyltransferase inhibitors, and model antiviral responses. It is valuable in dissecting the role of m6A modifications in inflammatory bowel disease, as demonstrated in recent METTL14 knockdown studies (Wu et al., 2024). In virology, it is an established tool for probing the methylation-dependence of viral replication in filoviruses such as Ebola and Marburg [EpigeneticsDomain]. Workflow-optimized for in vitro and in vivo models, the compound enables robust, reproducible modulation of methyltransferase activity (see EpigeneticsDomain for strategic guidance; this article provides updated translational context with new mechanistic evidence).

Common Pitfalls or Misconceptions

• Not a Clinical Therapeutic: 3-Deazaadenosine is not approved for clinical use in humans; it is for research only.
• Solubility Constraints: The compound is insoluble in ethanol and may precipitate at high concentrations or upon cooling from aqueous solution.
• Short-term Solution Stability: Solutions should be freshly prepared and used promptly; prolonged storage reduces activity.
• Non-selective Methyltransferase Inhibition: Inhibits all SAM-dependent methyltransferases, not specific isoforms.
• Does Not Inhibit Demethylases: 3-Deazaadenosine does not affect FTO or ALKBH5 demethylase activity.

Workflow Integration & Parameters

For in vitro studies, 3-Deazaadenosine is typically dissolved in DMSO at ≥26.6 mg/mL or in water at ≥7.53 mg/mL with gentle warming. Working concentrations depend on cell type and endpoint, commonly ranging from 1–100 μM. For animal models, dosing regimens are informed by prior efficacy in Ebola infection studies; detailed protocols are available from APExBIO (SKU B6121) [Product Page]. Storage at -20°C is mandatory for powder; solutions should be used within hours of preparation for maximal potency. Researchers can integrate 3-Deazaadenosine into workflows probing methylation in inflammation, cancer, or viral pathogenesis.

For deeper mechanistic insight into methyltransferase inhibition in viral models, see this Hexa-His article, which this guide extends with up-to-date solubility and workflow data.

Conclusion & Outlook

3-Deazaadenosine (APExBIO, SKU B6121) is a validated, potent SAH hydrolase inhibitor enabling precise, reproducible suppression of SAM-dependent methyltransferase activities. Its dual application in methylation research and preclinical antiviral models, including lethal Ebola infection, makes it a cornerstone reagent for epigenetic and virological discovery. Ongoing advances, especially in m6A RNA modification and inflammation, position 3-Deazaadenosine as a key experimental asset for dissecting methylation’s role in disease and therapy development. For validated protocols and ordering, refer to the APExBIO 3-Deazaadenosine product page.